Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Cumberland Partners Ltd

Cumberland Partners Ltd increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 47,326 shares of the pharmaceutical company’s stock after buying an additional 4,126 shares during the period. Vertex Pharmaceuticals comprises approximately 1.3% of Cumberland Partners Ltd’s holdings, making the stock its 22nd biggest position. Cumberland Partners Ltd’s holdings in Vertex Pharmaceuticals were worth $19,058,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of VRTX. Mutual Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after purchasing an additional 21 shares in the last quarter. Outlook Wealth Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock valued at $415,000 after buying an additional 24 shares in the last quarter. Dunhill Financial LLC boosted its stake in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares in the last quarter. Simon Quick Advisors LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.1% in the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company’s stock worth $900,000 after acquiring an additional 24 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Vertex Pharmaceuticals by 4.5% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 576 shares of the pharmaceutical company’s stock worth $268,000 after purchasing an additional 25 shares during the period. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. BMO Capital Markets reduced their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Truist Financial increased their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.57.

Insider Activity

In related news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $471.76 on Thursday. The company’s fifty day moving average is $435.32 and its 200-day moving average is $460.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.58 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.